BCYCBICYCLE THERAPEUTICS plc

Nasdaq bicycletherapeutics.com


$ 20.21 $ 0.06 (0.3 %)    

Thursday, 27-Jun-2024 15:59:49 EDT
QQQ $ 482.07 $ 1.24 (0.26 %)
DIA $ 391.62 $ 0.32 (0.08 %)
SPY $ 546.37 $ 0.86 (0.16 %)
TLT $ 93.57 $ 0.37 (0.4 %)
GLD $ 215.08 $ 2.41 (1.13 %)
$ 20.27
$ 20.05
$ 20.21 x 200
$ 0.00 x 0
$ 19.98 - $ 20.51
$ 12.54 - $ 27.50
174,394
na
862.69M
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-20-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-11-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-10-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bicycle-therapeutics-filed-a-prospectus-supplement-with-respect-to-resale-by-selling-securityholders-up-to-377m-ordinary-shares-with-each-ordinary-share-represented-by-1-american-depositary-share

- SEC Filing

 bicycle-therapeutics-reports-555m-private-placement-equity-financing-says-financing-includes-participation-from-new-and-existing-investors

The company has entered into a securities purchase agreement with certain existing and new accredited investors to issue and se...

 hc-wainwright--co-reiterates-buy-on-bicycle-therapeutics-maintains-55-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintain...

 bicycle-therapeutics-q1-2024-gaap-eps-062-beats-131-estimate-sales-19530m-beat-6029m-estimate

Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of ...

 needham-reiterates-buy-on-bicycle-therapeutics-maintains-43-price-target

Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $43 price target.

 walmart-to-rally-around-18-here-are-10-top-analyst-forecasts-for-wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 canaccord-genuity-reiterates-buy-on-bicycle-therapeutics-maintains-60-price-target

Canaccord Genuity analyst Bill Maughan reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $60 price target.

 hc-wainwright--co-maintains-buy-on-bicycle-therapeutics-lowers-price-target-to-55

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers th...

 needham-reiterates-buy-on-bicycle-therapeutics-maintains-43-price-target

Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $43 price target.

 jmp-securities-maintains-market-outperform-on-bicycle-therapeutics-lowers-price-target-to-32

JMP Securities analyst Reni Benjamin maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Market Outperform and lowers the pr...